Literature DB >> 9403719

NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

A E Sirica1, S Radaeva, N Caran.   

Abstract

Immunohistochemical studies have suggested that the tyrosine kinase growth factor receptor p185neu is overexpressed in a high percentage of human cholangiocarcinomas. To establish the specificity and temporal relationship between the expression of this receptor in cholangiocarcinogenesis, we investigated c-neu expression in precancerous cholangiofibrotic tissue and subsequently derived primary and transplantable cholangiocarcinomas originated in the livers of furan-treated rats. Proliferated bile ductules formed in rat models of bile ductular hyperplasia and the cell types of normal adult rat liver were also analyzed for c-neu expression. c-neu expression was not detected in normal adult rat liver by either Western blotting, immunohistochemistry, or in situ hybridization. In comparison, all of the cholangiocarcinomas analyzed, which were characterized by intestinal-type mucin-producing neoplastic glands, exhibited a prominent band with a molecular weight 185 kd, corresponding to p185neu. Only the neoplastic glandular epithelia of the cholangiocarcinomas showed a strong immunoreactivity for p185neu, which was predominantly localized to their cell surface but also observed cytoplasmically. In situ hybridization further revealed the cytoplasm of the tumor glandular epithelial cells to be strongly positive for c-neu mRNA transcripts. Of particular interest was our finding that c-neu is expressed early in furan cholangiocarcinogenesis, being more pronounced in the metaplastic intestinal glands of cholangiofibrotic tissue than in hyperplastic biliary epithelial cells in either the same tissue or in hyperplastic bile ductule tissue. Our results demonstrate that c-neu overexpression is a prominent feature of intestinal-type cholangiocarcinomas as well as of metaplastic intestinal glands that precede their development and is detected at lower levels in hyperplastic biliary epithelia. The overexpression of c-neu in the metaplastic and malignant neoplastic glands also correlated with their increased proliferating cell nuclear antigen (PCNA) labeling indices relative to those of hyperplastic biliary ducts and ductules and also appeared to correlate with their intestinal glandular pattern of differentiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403719      PMCID: PMC1858377     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  Evaluation of genotoxicity, pathological lesions, and cell proliferation in livers of rats and mice treated with furan.

Authors:  D M Wilson; T L Goldsworthy; J A Popp; B E Butterworth
Journal:  Environ Mol Mutagen       Date:  1992       Impact factor: 3.216

2.  c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study.

Authors:  V G Falck; W J Gullick
Journal:  J Pathol       Date:  1989-10       Impact factor: 7.996

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals.

Authors:  K Mortelmans; S Haworth; T Lawlor; W Speck; B Tainer; E Zeiger
Journal:  Environ Mutagen       Date:  1986

5.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

6.  Significance of intestinal metaplasia for the evolution of cancer in the biliary tract.

Authors:  S Kozuka; M Kurashina; M Tsubone; K Hachisuka; A Yasui
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

7.  The c-erb B-2 proto-oncogene in human pancreatic cancer.

Authors:  P A Hall; C M Hughes; S L Staddon; P I Richman; W J Gullick; N R Lemoine
Journal:  J Pathol       Date:  1990-07       Impact factor: 7.996

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method.

Authors:  A Nonomura; G Ohta; Y Nakanuma; R Izumi; Y Mizukami; F Matsubara; M Hayashi; K Watanabe; N Takayanagi
Journal:  Liver       Date:  1988-06

10.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3.

Authors:  C R King; I Borrello; F Bellot; P Comoglio; J Schlessinger
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

View more
  10 in total

1.  Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.

Authors:  Toru Kawamoto; Kazunori Ishige; Melanie Thomas; Yoriko Yamashita-Kashima; Sei Shu; Nobuyuki Ishikura; Shunichi Ariizumi; Masakazu Yamamoto; Kunihiko Kurosaki; Junichi Shoda
Journal:  J Gastroenterol       Date:  2014-08-12       Impact factor: 7.527

2.  Expression of an intestine-specific transcription factor (CDX1) in intestinal metaplasia and in subsequently developed intestinal type of cholangiocarcinoma in rat liver.

Authors:  P Ren; D G Silberg; A E Sirica
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.

Authors:  Takuya Kitamura; Kevin Connolly; Lynnsie Ruffino; Tetsuo Ajiki; Aline Lueckgen; John DiGiovanni; Kaoru Kiguchi
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

4.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

5.  Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions.

Authors:  P C de Groen; B Vroman; K Laakso; N F LaRusso
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-10       Impact factor: 2.416

Review 6.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

7.  HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer.

Authors:  Toru Kawamoto; Savitri Krishnamurthy; Emily Tarco; Smita Trivedi; Ignacio I Wistuba; Donghui Li; Ivan Roa; Juan C Roa; Melanie B Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-11

8.  HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis.

Authors:  Thomas Albrecht; Melina Rausch; Stephanie Rössler; Michael Albrecht; Jana Dorothea Braun; Veronika Geissler; Arianeb Mehrabi; Monika Nadja Vogel; Anita Pathil-Warth; Gunhild Mechtersheimer; Marcus Renner; Christian Rupp; Karl Heinz Weiss; Elena Busch; Bruno Köhler; Christoph Springfeld; Peter Schirmacher; Benjamin Goeppert
Journal:  BMC Cancer       Date:  2019-12-05       Impact factor: 4.430

Review 9.  Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Authors:  Rocio I R Macias
Journal:  ISRN Hepatol       Date:  2014-02-16

Review 10.  In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?

Authors:  Raphael Mohr; Burcin Özdirik; Jana Knorr; Alexander Wree; Münevver Demir; Frank Tacke; Christoph Roderburg
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.